| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adenoviruses, Human | 52 | 2023 | 255 | 13.100 |
Why?
|
| Corneal Diseases | 65 | 2024 | 542 | 12.320 |
Why?
|
| Cornea | 81 | 2024 | 1333 | 10.180 |
Why?
|
| Keratitis | 24 | 2024 | 241 | 8.650 |
Why?
|
| Prostheses and Implants | 51 | 2024 | 1271 | 6.570 |
Why?
|
| Stevens-Johnson Syndrome | 31 | 2024 | 246 | 6.320 |
Why?
|
| Adenovirus Infections, Human | 22 | 2020 | 73 | 5.820 |
Why?
|
| Artificial Organs | 24 | 2024 | 150 | 4.890 |
Why?
|
| Eye Infections, Bacterial | 15 | 2023 | 242 | 4.780 |
Why?
|
| Keratoconjunctivitis | 14 | 2021 | 40 | 4.560 |
Why?
|
| Prosthesis Implantation | 26 | 2024 | 592 | 4.190 |
Why?
|
| Adenoviridae Infections | 14 | 2022 | 93 | 4.030 |
Why?
|
| Eye Burns | 13 | 2024 | 65 | 3.960 |
Why?
|
| Burns, Chemical | 14 | 2024 | 123 | 3.950 |
Why?
|
| Corneal Ulcer | 13 | 2023 | 128 | 3.670 |
Why?
|
| Epithelium, Corneal | 13 | 2021 | 253 | 3.270 |
Why?
|
| Eye Infections, Viral | 8 | 2020 | 60 | 3.220 |
Why?
|
| Corneal Transplantation | 14 | 2021 | 321 | 3.200 |
Why?
|
| Ophthalmology | 14 | 2023 | 550 | 3.170 |
Why?
|
| Eye Diseases | 17 | 2023 | 653 | 3.120 |
Why?
|
| Keratitis, Herpetic | 7 | 2021 | 77 | 2.600 |
Why?
|
| Eye Infections, Fungal | 8 | 2023 | 100 | 2.440 |
Why?
|
| Limbus Corneae | 7 | 2021 | 144 | 2.430 |
Why?
|
| Genome, Viral | 25 | 2022 | 667 | 2.270 |
Why?
|
| Polymethyl Methacrylate | 10 | 2021 | 131 | 2.210 |
Why?
|
| Conjunctiva | 12 | 2019 | 479 | 2.090 |
Why?
|
| Visual Acuity | 40 | 2024 | 2672 | 1.960 |
Why?
|
| Endophthalmitis | 7 | 2023 | 260 | 1.890 |
Why?
|
| Capsid Proteins | 9 | 2016 | 468 | 1.870 |
Why?
|
| Glaucoma | 17 | 2023 | 1185 | 1.840 |
Why?
|
| Conjunctival Neoplasms | 8 | 2017 | 77 | 1.810 |
Why?
|
| Sterilization | 4 | 2021 | 133 | 1.740 |
Why?
|
| Recombination, Genetic | 12 | 2022 | 1519 | 1.710 |
Why?
|
| Adenoviridae | 9 | 2022 | 1084 | 1.660 |
Why?
|
| Blindness | 7 | 2023 | 584 | 1.610 |
Why?
|
| DNA, Viral | 22 | 2019 | 2202 | 1.440 |
Why?
|
| Keratoplasty, Penetrating | 9 | 2022 | 144 | 1.430 |
Why?
|
| Gelatin | 2 | 2021 | 220 | 1.370 |
Why?
|
| Amnion | 8 | 2024 | 197 | 1.270 |
Why?
|
| Eye Neoplasms | 5 | 2024 | 307 | 1.240 |
Why?
|
| Titanium | 6 | 2020 | 485 | 1.220 |
Why?
|
| Vitreous Body | 4 | 2015 | 399 | 1.220 |
Why?
|
| Evolution, Molecular | 13 | 2020 | 1886 | 1.150 |
Why?
|
| Conjunctival Diseases | 6 | 2019 | 110 | 1.140 |
Why?
|
| Anti-Bacterial Agents | 16 | 2023 | 7407 | 1.090 |
Why?
|
| Phylogeny | 26 | 2021 | 2811 | 1.070 |
Why?
|
| Conjunctivitis | 5 | 2022 | 155 | 1.060 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 5 | 2017 | 113 | 1.020 |
Why?
|
| Corneal Stroma | 7 | 2017 | 171 | 0.990 |
Why?
|
| Alkalies | 3 | 2017 | 44 | 0.970 |
Why?
|
| Methacrylates | 2 | 2021 | 109 | 0.950 |
Why?
|
| Cross-Linking Reagents | 4 | 2021 | 687 | 0.930 |
Why?
|
| Humans | 261 | 2024 | 761504 | 0.920 |
Why?
|
| Corneal Neovascularization | 4 | 2020 | 185 | 0.900 |
Why?
|
| Interleukin-8 | 5 | 2021 | 695 | 0.880 |
Why?
|
| Ophthalmologic Surgical Procedures | 10 | 2021 | 354 | 0.850 |
Why?
|
| Adenovirus E3 Proteins | 2 | 2013 | 7 | 0.840 |
Why?
|
| Eye Infections | 4 | 2023 | 62 | 0.820 |
Why?
|
| Adenoviruses, Simian | 5 | 2023 | 15 | 0.800 |
Why?
|
| Corneal Edema | 2 | 2020 | 47 | 0.780 |
Why?
|
| Stem Cell Transplantation | 4 | 2019 | 1600 | 0.770 |
Why?
|
| Tissue Engineering | 2 | 2021 | 1868 | 0.760 |
Why?
|
| Eye Proteins | 5 | 2019 | 633 | 0.760 |
Why?
|
| Chemokine CCL2 | 6 | 2010 | 605 | 0.750 |
Why?
|
| Eyelid Diseases | 6 | 2019 | 157 | 0.750 |
Why?
|
| Prosthesis Design | 9 | 2020 | 2115 | 0.750 |
Why?
|
| Adenovirus E1A Proteins | 2 | 2019 | 73 | 0.720 |
Why?
|
| Viral Tropism | 4 | 2019 | 102 | 0.700 |
Why?
|
| Neglected Diseases | 2 | 2021 | 66 | 0.690 |
Why?
|
| Herpes Zoster Ophthalmicus | 2 | 2021 | 37 | 0.690 |
Why?
|
| beta-Alanine | 1 | 2020 | 82 | 0.690 |
Why?
|
| Hemangioma, Capillary | 1 | 2020 | 64 | 0.680 |
Why?
|
| Therapies, Investigational | 1 | 2020 | 111 | 0.680 |
Why?
|
| School Admission Criteria | 1 | 2020 | 107 | 0.670 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2021 | 257 | 0.650 |
Why?
|
| Lymphoid Tissue | 4 | 2007 | 445 | 0.650 |
Why?
|
| Povidone-Iodine | 1 | 2019 | 55 | 0.650 |
Why?
|
| Biology | 1 | 2021 | 290 | 0.640 |
Why?
|
| Glucocorticoids | 9 | 2021 | 2161 | 0.640 |
Why?
|
| Benzoates | 1 | 2020 | 212 | 0.640 |
Why?
|
| Gamma Rays | 4 | 2021 | 318 | 0.630 |
Why?
|
| Personnel Selection | 1 | 2020 | 196 | 0.630 |
Why?
|
| Intraocular Pressure | 13 | 2023 | 1294 | 0.620 |
Why?
|
| Bioartificial Organs | 2 | 2015 | 47 | 0.620 |
Why?
|
| Rec A Recombinases | 1 | 2018 | 50 | 0.610 |
Why?
|
| Collagen | 4 | 2022 | 2638 | 0.610 |
Why?
|
| Microscopy, Confocal | 10 | 2020 | 1971 | 0.590 |
Why?
|
| Corneal Perforation | 2 | 2019 | 29 | 0.580 |
Why?
|
| Postoperative Complications | 15 | 2024 | 15631 | 0.570 |
Why?
|
| Viral Proteins | 6 | 2022 | 1804 | 0.570 |
Why?
|
| Intensive Care, Neonatal | 1 | 2019 | 199 | 0.560 |
Why?
|
| Glaucoma, Open-Angle | 2 | 2021 | 738 | 0.560 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2017 | 251 | 0.560 |
Why?
|
| Health Facilities | 2 | 2021 | 580 | 0.550 |
Why?
|
| Virus Internalization | 5 | 2020 | 497 | 0.550 |
Why?
|
| Sequence Analysis, DNA | 16 | 2019 | 4740 | 0.540 |
Why?
|
| Zinc Fingers | 1 | 2019 | 579 | 0.540 |
Why?
|
| Antifungal Agents | 5 | 2023 | 752 | 0.530 |
Why?
|
| Alternaria | 2 | 2013 | 42 | 0.530 |
Why?
|
| Neoplasms, Squamous Cell | 2 | 2008 | 95 | 0.530 |
Why?
|
| Chemokine CXCL1 | 3 | 2016 | 101 | 0.530 |
Why?
|
| Sjogren's Syndrome | 5 | 2017 | 237 | 0.520 |
Why?
|
| Eye Injuries | 4 | 2023 | 227 | 0.520 |
Why?
|
| Corneal Dystrophies, Hereditary | 3 | 2019 | 64 | 0.510 |
Why?
|
| Retrospective Studies | 51 | 2024 | 80636 | 0.510 |
Why?
|
| 5' Untranslated Regions | 1 | 2017 | 256 | 0.510 |
Why?
|
| Electrons | 3 | 2021 | 265 | 0.510 |
Why?
|
| Keratoconus | 2 | 2017 | 112 | 0.510 |
Why?
|
| Eyelid Neoplasms | 1 | 2017 | 89 | 0.510 |
Why?
|
| Light | 1 | 2021 | 1353 | 0.510 |
Why?
|
| Perforin | 1 | 2016 | 167 | 0.510 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2021 | 114 | 0.500 |
Why?
|
| Rosacea | 3 | 2004 | 59 | 0.500 |
Why?
|
| Burn Units | 1 | 2016 | 143 | 0.500 |
Why?
|
| Fas Ligand Protein | 1 | 2016 | 216 | 0.500 |
Why?
|
| Contact Lenses | 4 | 2021 | 138 | 0.490 |
Why?
|
| Hemangioma | 1 | 2020 | 727 | 0.490 |
Why?
|
| Microsurgery | 1 | 2020 | 795 | 0.480 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2012 | 66 | 0.480 |
Why?
|
| Search Engine | 4 | 2022 | 143 | 0.480 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2019 | 1048 | 0.470 |
Why?
|
| Bacteria | 4 | 2023 | 2199 | 0.470 |
Why?
|
| Schools, Medical | 1 | 2021 | 879 | 0.470 |
Why?
|
| Stem Cells | 3 | 2021 | 3522 | 0.460 |
Why?
|
| Granzymes | 1 | 2016 | 277 | 0.460 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2015 | 97 | 0.460 |
Why?
|
| RNA, Viral | 5 | 2017 | 2846 | 0.450 |
Why?
|
| Cicatrix | 1 | 2020 | 798 | 0.450 |
Why?
|
| Biological Evolution | 1 | 2019 | 1071 | 0.450 |
Why?
|
| Computational Biology | 16 | 2019 | 3518 | 0.450 |
Why?
|
| Descemet Stripping Endothelial Keratoplasty | 3 | 2022 | 112 | 0.450 |
Why?
|
| Disease Outbreaks | 7 | 2023 | 1749 | 0.440 |
Why?
|
| Educational Measurement | 1 | 2020 | 1254 | 0.440 |
Why?
|
| Retina | 9 | 2020 | 2659 | 0.430 |
Why?
|
| Health Personnel | 2 | 2021 | 3335 | 0.430 |
Why?
|
| Fluorescein Angiography | 1 | 2019 | 1059 | 0.430 |
Why?
|
| Keloid | 1 | 2013 | 54 | 0.430 |
Why?
|
| Carbonic Anhydrase Inhibitors | 2 | 2018 | 91 | 0.430 |
Why?
|
| Sweet Syndrome | 1 | 2013 | 58 | 0.420 |
Why?
|
| Fibroblasts | 9 | 2021 | 4141 | 0.420 |
Why?
|
| Mouth Diseases | 1 | 2015 | 241 | 0.410 |
Why?
|
| Anterior Eye Segment | 3 | 2020 | 143 | 0.410 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 10 | 2019 | 3810 | 0.410 |
Why?
|
| Cryotherapy | 2 | 2011 | 159 | 0.400 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2016 | 587 | 0.400 |
Why?
|
| Host-Pathogen Interactions | 2 | 2021 | 1459 | 0.390 |
Why?
|
| Acetazolamide | 1 | 2012 | 96 | 0.390 |
Why?
|
| Critical Pathways | 1 | 2015 | 474 | 0.390 |
Why?
|
| Disease Models, Animal | 13 | 2023 | 18252 | 0.390 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2019 | 846 | 0.390 |
Why?
|
| Tomography, Optical Coherence | 8 | 2023 | 2917 | 0.380 |
Why?
|
| Acanthamoeba Keratitis | 2 | 2021 | 13 | 0.380 |
Why?
|
| Rabbits | 11 | 2023 | 4772 | 0.380 |
Why?
|
| Artificial Intelligence | 3 | 2020 | 2578 | 0.380 |
Why?
|
| Animals | 57 | 2023 | 168459 | 0.380 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2020 | 636 | 0.380 |
Why?
|
| Bacterial Infections | 1 | 2019 | 1390 | 0.380 |
Why?
|
| Surface Properties | 5 | 2021 | 1161 | 0.380 |
Why?
|
| Biological Dressings | 1 | 2011 | 30 | 0.370 |
Why?
|
| Lacerations | 1 | 2013 | 147 | 0.370 |
Why?
|
| Monocytes | 5 | 2023 | 2570 | 0.360 |
Why?
|
| Microglia | 4 | 2021 | 1361 | 0.360 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 2024 | 0.360 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2011 | 490 | 0.350 |
Why?
|
| Middle Aged | 61 | 2024 | 220895 | 0.350 |
Why?
|
| Antiviral Agents | 3 | 2020 | 3060 | 0.350 |
Why?
|
| Administration, Topical | 5 | 2013 | 704 | 0.340 |
Why?
|
| Ultraviolet Rays | 5 | 2022 | 1080 | 0.340 |
Why?
|
| Female | 84 | 2024 | 392644 | 0.340 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2009 | 57 | 0.340 |
Why?
|
| Algorithms | 4 | 2020 | 14031 | 0.330 |
Why?
|
| Respiratory Tract Infections | 4 | 2016 | 1010 | 0.330 |
Why?
|
| Immunity, Innate | 3 | 2019 | 3065 | 0.330 |
Why?
|
| Tissue Scaffolds | 3 | 2021 | 934 | 0.330 |
Why?
|
| Gene Expression Regulation, Viral | 4 | 2019 | 439 | 0.330 |
Why?
|
| Dendritic Cells | 3 | 2016 | 2747 | 0.330 |
Why?
|
| Male | 80 | 2024 | 360804 | 0.330 |
Why?
|
| Hydrogels | 3 | 2021 | 720 | 0.330 |
Why?
|
| Visually Impaired Persons | 1 | 2010 | 78 | 0.330 |
Why?
|
| Pandemics | 5 | 2022 | 8654 | 0.330 |
Why?
|
| Neuroglia | 3 | 2020 | 956 | 0.330 |
Why?
|
| Sequence Alignment | 7 | 2019 | 2180 | 0.320 |
Why?
|
| Aged | 50 | 2024 | 169289 | 0.320 |
Why?
|
| Epitopes | 1 | 2015 | 2503 | 0.320 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2012 | 687 | 0.320 |
Why?
|
| Acute Disease | 11 | 2024 | 7237 | 0.320 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 1784 | 0.310 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 4026 | 0.310 |
Why?
|
| Societies, Medical | 1 | 2020 | 3905 | 0.310 |
Why?
|
| Bowman Membrane | 1 | 2008 | 2 | 0.310 |
Why?
|
| Adult | 58 | 2024 | 221177 | 0.310 |
Why?
|
| RNA, Messenger | 6 | 2017 | 12795 | 0.310 |
Why?
|
| Follow-Up Studies | 22 | 2024 | 39106 | 0.300 |
Why?
|
| Eyelids | 4 | 2020 | 278 | 0.300 |
Why?
|
| Clinical Competence | 2 | 2020 | 4792 | 0.300 |
Why?
|
| Virus Replication | 8 | 2019 | 2435 | 0.300 |
Why?
|
| Fungi | 1 | 2011 | 338 | 0.300 |
Why?
|
| Respiratory Tract Diseases | 1 | 2013 | 750 | 0.300 |
Why?
|
| Tears | 4 | 2017 | 251 | 0.300 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 942 | 0.290 |
Why?
|
| Sarcoma, Kaposi | 1 | 2011 | 374 | 0.290 |
Why?
|
| Capsid | 1 | 2010 | 435 | 0.290 |
Why?
|
| Laser Therapy | 2 | 2013 | 1092 | 0.290 |
Why?
|
| Autoimmune Diseases | 4 | 2021 | 2244 | 0.290 |
Why?
|
| Macrophages | 4 | 2023 | 5769 | 0.280 |
Why?
|
| Tetracyclines | 2 | 2004 | 64 | 0.280 |
Why?
|
| Electronic Health Records | 4 | 2019 | 4811 | 0.280 |
Why?
|
| Riboflavin | 3 | 2017 | 107 | 0.280 |
Why?
|
| Dry Eye Syndromes | 3 | 2023 | 387 | 0.280 |
Why?
|
| Cells, Cultured | 12 | 2021 | 18965 | 0.270 |
Why?
|
| NF-kappa B | 4 | 2009 | 2490 | 0.270 |
Why?
|
| Cataract Extraction | 1 | 2011 | 467 | 0.270 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 1200 | 0.270 |
Why?
|
| Liver Diseases | 1 | 2015 | 1298 | 0.270 |
Why?
|
| Interferon-alpha | 2 | 2008 | 921 | 0.270 |
Why?
|
| Protein Subunits | 1 | 2009 | 943 | 0.270 |
Why?
|
| Vitronectin | 1 | 2005 | 40 | 0.260 |
Why?
|
| Gelatinases | 2 | 2018 | 88 | 0.260 |
Why?
|
| Escherichia coli | 1 | 2018 | 4217 | 0.260 |
Why?
|
| Tropism | 1 | 2005 | 44 | 0.260 |
Why?
|
| Eye | 4 | 2022 | 712 | 0.260 |
Why?
|
| Hospitals, Special | 1 | 2006 | 91 | 0.250 |
Why?
|
| Scleritis | 2 | 2017 | 96 | 0.250 |
Why?
|
| Fever | 1 | 2013 | 1618 | 0.250 |
Why?
|
| Oligopeptides | 2 | 2012 | 1187 | 0.250 |
Why?
|
| Glaucoma Drainage Implants | 2 | 2019 | 107 | 0.250 |
Why?
|
| Acyclovir | 2 | 2020 | 268 | 0.250 |
Why?
|
| Peroxidase | 3 | 2016 | 609 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 12 | 2020 | 22169 | 0.250 |
Why?
|
| Matrix Metalloproteinases | 2 | 2019 | 393 | 0.240 |
Why?
|
| Base Sequence | 12 | 2018 | 12441 | 0.240 |
Why?
|
| Lung Diseases | 1 | 2015 | 1909 | 0.240 |
Why?
|
| Disease Management | 1 | 2015 | 2508 | 0.240 |
Why?
|
| Internet | 5 | 2022 | 3092 | 0.240 |
Why?
|
| Temperature | 2 | 2021 | 2226 | 0.240 |
Why?
|
| Treatment Outcome | 17 | 2024 | 64680 | 0.240 |
Why?
|
| Neutrophils | 2 | 2009 | 3767 | 0.240 |
Why?
|
| Fasciitis | 1 | 2005 | 67 | 0.230 |
Why?
|
| Retinal Diseases | 3 | 2018 | 705 | 0.230 |
Why?
|
| Kidney Diseases | 1 | 2015 | 2091 | 0.230 |
Why?
|
| Cross Infection | 2 | 2020 | 1422 | 0.230 |
Why?
|
| Aged, 80 and over | 20 | 2024 | 58976 | 0.230 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2010 | 4575 | 0.230 |
Why?
|
| Iris Diseases | 1 | 2004 | 37 | 0.220 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 1923 | 0.220 |
Why?
|
| Molecular Sequence Data | 15 | 2013 | 17635 | 0.220 |
Why?
|
| Blood Proteins | 3 | 2018 | 1173 | 0.220 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 441 | 0.220 |
Why?
|
| Ophthalmic Solutions | 6 | 2023 | 313 | 0.220 |
Why?
|
| Internship and Residency | 2 | 2020 | 5880 | 0.220 |
Why?
|
| Vaccines | 2 | 2023 | 844 | 0.220 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2003 | 2425 | 0.220 |
Why?
|
| Sporothrix | 1 | 2002 | 3 | 0.210 |
Why?
|
| Sporotrichosis | 1 | 2002 | 3 | 0.210 |
Why?
|
| Skin | 2 | 2016 | 4484 | 0.210 |
Why?
|
| Ferric Compounds | 1 | 2005 | 378 | 0.210 |
Why?
|
| Administration, Oral | 5 | 2020 | 4021 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2023 | 4352 | 0.210 |
Why?
|
| Organic Chemicals | 2 | 2021 | 210 | 0.210 |
Why?
|
| Transplantation, Autologous | 3 | 2019 | 2115 | 0.210 |
Why?
|
| Smallpox | 1 | 2023 | 43 | 0.210 |
Why?
|
| Melanosis | 1 | 2004 | 93 | 0.210 |
Why?
|
| Dynamin II | 2 | 2020 | 35 | 0.210 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 2 | 2021 | 161 | 0.210 |
Why?
|
| Vaccinia | 1 | 2023 | 71 | 0.210 |
Why?
|
| Antiprotozoal Agents | 2 | 2020 | 94 | 0.200 |
Why?
|
| Caprolactam | 1 | 2021 | 1 | 0.200 |
Why?
|
| Carbapenems | 1 | 2023 | 123 | 0.200 |
Why?
|
| Intensive Care Units | 1 | 2016 | 3745 | 0.200 |
Why?
|
| Graft Rejection | 1 | 2015 | 4445 | 0.200 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2016 | 233 | 0.200 |
Why?
|
| Information Dissemination | 1 | 2010 | 1126 | 0.200 |
Why?
|
| Biocompatible Materials | 5 | 2021 | 1685 | 0.200 |
Why?
|
| Virulence | 3 | 2022 | 1303 | 0.200 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2021 | 69 | 0.200 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2016 | 148 | 0.200 |
Why?
|
| Mycoplasma | 1 | 2022 | 147 | 0.200 |
Why?
|
| Flow Cytometry | 5 | 2015 | 5869 | 0.190 |
Why?
|
| Ochrobactrum anthropi | 1 | 2021 | 2 | 0.190 |
Why?
|
| Facial Transplantation | 1 | 2024 | 221 | 0.190 |
Why?
|
| Incidence | 10 | 2024 | 21353 | 0.190 |
Why?
|
| Thermogravimetry | 1 | 2021 | 7 | 0.190 |
Why?
|
| Corynebacterium Infections | 1 | 2021 | 27 | 0.190 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 1527 | 0.190 |
Why?
|
| Bioprosthesis | 2 | 2016 | 591 | 0.190 |
Why?
|
| Papio | 1 | 2003 | 669 | 0.190 |
Why?
|
| Ethanolamines | 1 | 2021 | 153 | 0.190 |
Why?
|
| Parasitic Diseases | 1 | 2021 | 76 | 0.190 |
Why?
|
| Sclera | 2 | 2020 | 190 | 0.190 |
Why?
|
| Tropical Medicine | 1 | 2021 | 51 | 0.190 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2018 | 1809 | 0.190 |
Why?
|
| Epoxy Compounds | 1 | 2021 | 137 | 0.190 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2021 | 100 | 0.190 |
Why?
|
| Optic Nerve | 2 | 2023 | 572 | 0.190 |
Why?
|
| Pyrrolidinones | 1 | 2021 | 116 | 0.190 |
Why?
|
| Complement C5 | 1 | 2021 | 103 | 0.190 |
Why?
|
| Prednisolone | 2 | 2013 | 326 | 0.190 |
Why?
|
| Meibomian Glands | 2 | 2016 | 73 | 0.180 |
Why?
|
| Ulcer | 1 | 2002 | 204 | 0.180 |
Why?
|
| Keratoconjunctivitis, Infectious | 1 | 2020 | 1 | 0.180 |
Why?
|
| Mucositis | 1 | 2022 | 108 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 6 | 2023 | 6075 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 9280 | 0.180 |
Why?
|
| Fusarium | 1 | 2020 | 51 | 0.180 |
Why?
|
| Graft Survival | 5 | 2016 | 3819 | 0.180 |
Why?
|
| src-Family Kinases | 3 | 2016 | 535 | 0.180 |
Why?
|
| Ciliary Body | 2 | 2021 | 167 | 0.180 |
Why?
|
| Enzyme Activation | 5 | 2009 | 3597 | 0.180 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2021 | 1937 | 0.180 |
Why?
|
| Biopsy | 5 | 2017 | 6766 | 0.180 |
Why?
|
| Astigmatism | 1 | 2020 | 68 | 0.180 |
Why?
|
| Organogenesis | 1 | 2021 | 215 | 0.180 |
Why?
|
| Microscopy, Atomic Force | 1 | 2021 | 253 | 0.180 |
Why?
|
| Conserved Sequence | 3 | 2019 | 1163 | 0.180 |
Why?
|
| Eye Evisceration | 1 | 2019 | 22 | 0.170 |
Why?
|
| Onchocerciasis, Ocular | 1 | 2019 | 7 | 0.170 |
Why?
|
| Immunohistochemistry | 8 | 2013 | 11076 | 0.170 |
Why?
|
| Phosphorylcholine | 1 | 2020 | 153 | 0.170 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2014 | 664 | 0.170 |
Why?
|
| Epidemics | 2 | 2019 | 512 | 0.170 |
Why?
|
| Gonioscopy | 1 | 2020 | 155 | 0.170 |
Why?
|
| Trachoma | 1 | 2019 | 18 | 0.170 |
Why?
|
| Hydroxyapatites | 1 | 2020 | 73 | 0.170 |
Why?
|
| Standard of Care | 1 | 2024 | 551 | 0.170 |
Why?
|
| Eye Enucleation | 1 | 2019 | 128 | 0.170 |
Why?
|
| Peer Review | 1 | 2022 | 217 | 0.170 |
Why?
|
| Mice | 19 | 2021 | 81525 | 0.170 |
Why?
|
| Contact Lenses, Hydrophilic | 2 | 2020 | 54 | 0.170 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2019 | 344 | 0.170 |
Why?
|
| Young Adult | 19 | 2024 | 59243 | 0.170 |
Why?
|
| Lubricants | 1 | 2019 | 26 | 0.170 |
Why?
|
| Photochemotherapy | 2 | 2017 | 823 | 0.170 |
Why?
|
| Genomics | 6 | 2020 | 5821 | 0.170 |
Why?
|
| Aniridia | 1 | 2019 | 36 | 0.170 |
Why?
|
| Leprosy | 1 | 2019 | 126 | 0.160 |
Why?
|
| Aspergillus fumigatus | 1 | 2020 | 157 | 0.160 |
Why?
|
| Corneal Surgery, Laser | 1 | 2019 | 11 | 0.160 |
Why?
|
| Chemokines | 3 | 2012 | 960 | 0.160 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2021 | 238 | 0.160 |
Why?
|
| Cyanoacrylates | 1 | 2019 | 46 | 0.160 |
Why?
|
| Complement Activation | 1 | 2021 | 445 | 0.160 |
Why?
|
| Specialty Boards | 1 | 2020 | 235 | 0.160 |
Why?
|
| Pseudomonas Infections | 1 | 2023 | 622 | 0.160 |
Why?
|
| Patient Care Team | 2 | 2020 | 2521 | 0.160 |
Why?
|
| Eye, Artificial | 1 | 2018 | 18 | 0.160 |
Why?
|
| Immunity, Mucosal | 1 | 2002 | 483 | 0.160 |
Why?
|
| Retinal Ganglion Cells | 4 | 2023 | 811 | 0.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2016 | 151 | 0.160 |
Why?
|
| rho-Associated Kinases | 1 | 2020 | 281 | 0.160 |
Why?
|
| Human Rights | 1 | 2021 | 309 | 0.160 |
Why?
|
| Sequence Homology | 4 | 2013 | 196 | 0.150 |
Why?
|
| Blogging | 1 | 2018 | 15 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7390 | 0.150 |
Why?
|
| Inflammation Mediators | 2 | 2018 | 1886 | 0.150 |
Why?
|
| Cluster Analysis | 5 | 2013 | 2707 | 0.150 |
Why?
|
| Education, Medical, Graduate | 2 | 2020 | 2373 | 0.150 |
Why?
|
| Diagnosis, Differential | 5 | 2019 | 12974 | 0.150 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2005 | 1741 | 0.150 |
Why?
|
| Child | 16 | 2020 | 80153 | 0.150 |
Why?
|
| Phosphorylation | 6 | 2007 | 8320 | 0.150 |
Why?
|
| Evidence-Based Medicine | 3 | 2020 | 3688 | 0.150 |
Why?
|
| Substance P | 1 | 2019 | 335 | 0.150 |
Why?
|
| Health Care Surveys | 1 | 2005 | 2426 | 0.150 |
Why?
|
| Candida albicans | 1 | 2020 | 372 | 0.150 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2017 | 27 | 0.150 |
Why?
|
| Tissue Adhesives | 2 | 2024 | 173 | 0.150 |
Why?
|
| Optic Nerve Injuries | 1 | 2018 | 150 | 0.140 |
Why?
|
| Seasons | 3 | 2018 | 1520 | 0.140 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2020 | 695 | 0.140 |
Why?
|
| Tonometry, Ocular | 4 | 2022 | 235 | 0.140 |
Why?
|
| Population Surveillance | 2 | 2019 | 2598 | 0.140 |
Why?
|
| Exanthema | 1 | 2022 | 503 | 0.140 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.140 |
Why?
|
| United States | 11 | 2022 | 72334 | 0.140 |
Why?
|
| Disinfection | 1 | 2019 | 211 | 0.140 |
Why?
|
| Fundus Oculi | 1 | 2019 | 556 | 0.140 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2018 | 125 | 0.140 |
Why?
|
| Base Composition | 1 | 2017 | 290 | 0.140 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2019 | 191 | 0.140 |
Why?
|
| Protein Transport | 3 | 2012 | 1967 | 0.140 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 1738 | 0.140 |
Why?
|
| Transcription Factor RelA | 2 | 2009 | 254 | 0.140 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 1 | 2016 | 4 | 0.140 |
Why?
|
| Chronic Disease | 5 | 2021 | 9318 | 0.140 |
Why?
|
| Cost Control | 1 | 2019 | 628 | 0.140 |
Why?
|
| Photosensitizing Agents | 3 | 2017 | 623 | 0.130 |
Why?
|
| Cell Line | 6 | 2020 | 15601 | 0.130 |
Why?
|
| Hyperplasia | 2 | 2013 | 1152 | 0.130 |
Why?
|
| Aging | 1 | 2015 | 8708 | 0.130 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2016 | 94 | 0.130 |
Why?
|
| Stromal Cells | 1 | 2021 | 1330 | 0.130 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2018 | 330 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 2865 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2020 | 617 | 0.130 |
Why?
|
| Galectin 3 | 1 | 2018 | 240 | 0.130 |
Why?
|
| Metagenomics | 1 | 2019 | 467 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 4016 | 0.130 |
Why?
|
| Stress, Mechanical | 1 | 2021 | 1674 | 0.130 |
Why?
|
| Cell Survival | 2 | 2021 | 5791 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2019 | 1651 | 0.130 |
Why?
|
| Amino Acid Sequence | 5 | 2016 | 13446 | 0.130 |
Why?
|
| Mice, Knockout | 5 | 2017 | 14414 | 0.130 |
Why?
|
| Axons | 1 | 2023 | 1674 | 0.130 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 108 | 0.130 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2016 | 262 | 0.130 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2023 | 1277 | 0.120 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2019 | 828 | 0.120 |
Why?
|
| Expert Testimony | 1 | 2018 | 364 | 0.120 |
Why?
|
| Triamcinolone | 1 | 1995 | 68 | 0.120 |
Why?
|
| Recombinant Proteins | 4 | 2011 | 6534 | 0.120 |
Why?
|
| Male Urogenital Diseases | 1 | 2015 | 48 | 0.120 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 13639 | 0.120 |
Why?
|
| Protein Binding | 3 | 2021 | 9351 | 0.120 |
Why?
|
| Laser Coagulation | 1 | 2017 | 330 | 0.120 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2015 | 49 | 0.120 |
Why?
|
| Nanostructures | 1 | 2020 | 553 | 0.120 |
Why?
|
| Genotype | 4 | 2018 | 12990 | 0.120 |
Why?
|
| Staphylococcal Infections | 2 | 2020 | 1408 | 0.120 |
Why?
|
| Adolescent | 16 | 2024 | 88319 | 0.120 |
Why?
|
| Granuloma | 1 | 2017 | 328 | 0.120 |
Why?
|
| Lasers, Excimer | 1 | 2015 | 69 | 0.120 |
Why?
|
| Swine | 6 | 2021 | 5915 | 0.120 |
Why?
|
| Necrosis | 2 | 2016 | 1611 | 0.120 |
Why?
|
| Dermatitis, Atopic | 1 | 2022 | 731 | 0.120 |
Why?
|
| Water | 1 | 2021 | 1411 | 0.120 |
Why?
|
| Retinal Degeneration | 1 | 2018 | 413 | 0.120 |
Why?
|
| Hematopoiesis | 2 | 2021 | 2049 | 0.120 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2016 | 347 | 0.120 |
Why?
|
| Basement Membrane | 1 | 2015 | 349 | 0.120 |
Why?
|
| Exudates and Transudates | 2 | 2014 | 174 | 0.120 |
Why?
|
| Transplantation, Heterologous | 2 | 2021 | 2385 | 0.120 |
Why?
|
| Carrier Proteins | 2 | 2004 | 4936 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2019 | 1699 | 0.110 |
Why?
|
| Apoptosis | 5 | 2023 | 9486 | 0.110 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2015 | 84 | 0.110 |
Why?
|
| Acanthamoeba castellanii | 1 | 2013 | 9 | 0.110 |
Why?
|
| Trigeminal Nerve | 1 | 2015 | 248 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2023 | 3395 | 0.110 |
Why?
|
| Genital Diseases, Female | 1 | 2015 | 192 | 0.110 |
Why?
|
| Gene Expression | 4 | 2021 | 7581 | 0.110 |
Why?
|
| Open Reading Frames | 1 | 2017 | 815 | 0.110 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2020 | 698 | 0.110 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2013 | 56 | 0.110 |
Why?
|
| Prosthesis Coloring | 1 | 2013 | 29 | 0.110 |
Why?
|
| Inflammation | 3 | 2021 | 10773 | 0.110 |
Why?
|
| Nucleic Acid Conformation | 1 | 2017 | 902 | 0.110 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2014 | 72 | 0.110 |
Why?
|
| Histiocytes | 1 | 2013 | 98 | 0.110 |
Why?
|
| Interferon Type I | 1 | 2017 | 562 | 0.110 |
Why?
|
| Physician Executives | 1 | 2014 | 134 | 0.110 |
Why?
|
| Regeneration | 1 | 2022 | 1511 | 0.110 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 733 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2006 | 473 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 4511 | 0.110 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 3358 | 0.110 |
Why?
|
| Chemokines, CXC | 2 | 2006 | 422 | 0.110 |
Why?
|
| Epidermis | 1 | 2016 | 528 | 0.110 |
Why?
|
| Developing Countries | 2 | 2019 | 2885 | 0.110 |
Why?
|
| Vision Disorders | 1 | 2020 | 1088 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2006 | 477 | 0.100 |
Why?
|
| Zoonoses | 3 | 2020 | 179 | 0.100 |
Why?
|
| Blotting, Western | 4 | 2016 | 5035 | 0.100 |
Why?
|
| Monkeypox virus | 2 | 2023 | 42 | 0.100 |
Why?
|
| Models, Immunological | 1 | 2015 | 513 | 0.100 |
Why?
|
| Ocular Hypertension | 1 | 2014 | 209 | 0.100 |
Why?
|
| Actins | 1 | 2020 | 2050 | 0.100 |
Why?
|
| Corneal Opacity | 1 | 2013 | 47 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2019 | 1756 | 0.100 |
Why?
|
| AIDS Vaccines | 1 | 2019 | 896 | 0.100 |
Why?
|
| Cysts | 2 | 2017 | 681 | 0.100 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2013 | 145 | 0.100 |
Why?
|
| Goblet Cells | 1 | 2016 | 298 | 0.100 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 469 | 0.100 |
Why?
|
| Descemet Membrane | 1 | 2013 | 71 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3084 | 0.100 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2018 | 427 | 0.100 |
Why?
|
| User-Computer Interface | 1 | 2019 | 1400 | 0.100 |
Why?
|
| Myopia | 1 | 2015 | 253 | 0.100 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3204 | 0.100 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 5336 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2012 | 103 | 0.100 |
Why?
|
| Wet Macular Degeneration | 1 | 2014 | 162 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 1403 | 0.100 |
Why?
|
| Risk Factors | 7 | 2024 | 74206 | 0.100 |
Why?
|
| China | 4 | 2024 | 2369 | 0.100 |
Why?
|
| Cell Adhesion | 2 | 2016 | 3087 | 0.100 |
Why?
|
| Caveolin 1 | 1 | 2013 | 256 | 0.100 |
Why?
|
| Myofibroblasts | 1 | 2013 | 223 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2016 | 549 | 0.100 |
Why?
|
| Medical Informatics | 1 | 2019 | 733 | 0.100 |
Why?
|
| Neuroprotective Agents | 3 | 2018 | 957 | 0.100 |
Why?
|
| DNA Replication | 1 | 2018 | 1418 | 0.100 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2013 | 213 | 0.100 |
Why?
|
| Magnetite Nanoparticles | 1 | 2013 | 318 | 0.090 |
Why?
|
| Polychondritis, Relapsing | 1 | 2011 | 29 | 0.090 |
Why?
|
| Electromagnetic Fields | 1 | 2013 | 296 | 0.090 |
Why?
|
| Uvea | 2 | 2017 | 30 | 0.090 |
Why?
|
| Ophthalmic Nerve | 1 | 2011 | 42 | 0.090 |
Why?
|
| Retinal Detachment | 1 | 2015 | 428 | 0.090 |
Why?
|
| Endothelium, Corneal | 3 | 2022 | 215 | 0.090 |
Why?
|
| Trimethoprim | 2 | 2021 | 78 | 0.090 |
Why?
|
| Communicable Diseases | 1 | 2019 | 875 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 1880 | 0.090 |
Why?
|
| Leukocytes | 2 | 2010 | 2026 | 0.090 |
Why?
|
| Antibodies, Antinuclear | 1 | 2012 | 343 | 0.090 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2013 | 191 | 0.090 |
Why?
|
| Nerve Degeneration | 1 | 2015 | 748 | 0.090 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2013 | 124 | 0.090 |
Why?
|
| Cytokines | 3 | 2021 | 7396 | 0.090 |
Why?
|
| Immunoblotting | 2 | 2005 | 1646 | 0.090 |
Why?
|
| Dimethylallyltranstransferase | 1 | 2010 | 8 | 0.090 |
Why?
|
| Alginates | 1 | 2012 | 248 | 0.090 |
Why?
|
| Genetic Variation | 3 | 2017 | 6567 | 0.090 |
Why?
|
| Molecular Chaperones | 2 | 2022 | 754 | 0.090 |
Why?
|
| Eye Abnormalities | 1 | 2013 | 242 | 0.090 |
Why?
|
| Hypertrophy | 1 | 2012 | 561 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 2199 | 0.090 |
Why?
|
| Durapatite | 1 | 2011 | 163 | 0.090 |
Why?
|
| Ecosystem | 1 | 2014 | 490 | 0.090 |
Why?
|
| Choroid | 1 | 2012 | 360 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2012 | 23445 | 0.090 |
Why?
|
| Infant, Newborn | 5 | 2019 | 26198 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 6310 | 0.080 |
Why?
|
| Ribonucleoproteins | 1 | 2012 | 372 | 0.080 |
Why?
|
| DNA, Fungal | 1 | 2011 | 275 | 0.080 |
Why?
|
| Nerve Regeneration | 1 | 2015 | 795 | 0.080 |
Why?
|
| Tyrosine | 2 | 2005 | 1440 | 0.080 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 1087 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2021 | 1852 | 0.080 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2011 | 312 | 0.080 |
Why?
|
| France | 1 | 2010 | 497 | 0.080 |
Why?
|
| Comorbidity | 2 | 2021 | 10508 | 0.080 |
Why?
|
| Virus Activation | 1 | 2011 | 322 | 0.080 |
Why?
|
| Brachytherapy | 1 | 2017 | 1223 | 0.080 |
Why?
|
| Massachusetts | 3 | 2020 | 8830 | 0.080 |
Why?
|
| Antigens, Viral | 2 | 2011 | 988 | 0.080 |
Why?
|
| Species Specificity | 3 | 2020 | 2414 | 0.080 |
Why?
|
| Morbidity | 3 | 2020 | 1750 | 0.080 |
Why?
|
| Physician's Role | 1 | 2016 | 917 | 0.080 |
Why?
|
| Quantitative Trait Loci | 1 | 2017 | 2116 | 0.080 |
Why?
|
| Epithelium | 2 | 2005 | 1603 | 0.080 |
Why?
|
| Genes, Viral | 1 | 2010 | 649 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2022 | 3429 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2015 | 8529 | 0.080 |
Why?
|
| Transplantation, Homologous | 2 | 2024 | 4806 | 0.080 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 726 | 0.080 |
Why?
|
| I-kappa B Kinase | 1 | 2009 | 250 | 0.080 |
Why?
|
| Prednisone | 1 | 2013 | 1563 | 0.080 |
Why?
|
| Kinetics | 2 | 2021 | 6374 | 0.080 |
Why?
|
| Public Health Practice | 1 | 2010 | 219 | 0.080 |
Why?
|
| Mice, Inbred C3H | 1 | 2009 | 915 | 0.080 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2008 | 44 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 662 | 0.080 |
Why?
|
| Age of Onset | 1 | 2015 | 3305 | 0.080 |
Why?
|
| Keratinocytes | 1 | 2012 | 790 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2007 | 613 | 0.080 |
Why?
|
| Mycophenolic Acid | 1 | 2010 | 348 | 0.080 |
Why?
|
| Vascular Malformations | 1 | 2013 | 468 | 0.080 |
Why?
|
| Autoantigens | 1 | 2012 | 891 | 0.080 |
Why?
|
| Synaptotagmin I | 1 | 2008 | 33 | 0.070 |
Why?
|
| Transcription, Genetic | 2 | 2017 | 7594 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 11903 | 0.070 |
Why?
|
| Recurrence | 3 | 2011 | 8465 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 9539 | 0.070 |
Why?
|
| Herpesvirus 1, Human | 2 | 2011 | 753 | 0.070 |
Why?
|
| Health Promotion | 1 | 2019 | 2214 | 0.070 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2007 | 14 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2020 | 3548 | 0.070 |
Why?
|
| Chemokine CXCL10 | 2 | 2006 | 316 | 0.070 |
Why?
|
| Serpins | 1 | 2009 | 247 | 0.070 |
Why?
|
| Nerve Fibers | 3 | 2023 | 708 | 0.070 |
Why?
|
| I-kappa B Proteins | 1 | 2008 | 211 | 0.070 |
Why?
|
| Inpatients | 1 | 2019 | 2548 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3639 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 2 | 2019 | 256 | 0.070 |
Why?
|
| Mycoses | 1 | 2010 | 386 | 0.070 |
Why?
|
| Neutrophil Infiltration | 1 | 2009 | 390 | 0.070 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2009 | 855 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2013 | 1440 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 2748 | 0.070 |
Why?
|
| Publishing | 1 | 2014 | 833 | 0.070 |
Why?
|
| Cross-Sectional Studies | 8 | 2021 | 26125 | 0.070 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2009 | 662 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2012 | 710 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2013 | 3028 | 0.070 |
Why?
|
| Wound Healing | 2 | 2020 | 2805 | 0.070 |
Why?
|
| RNA Splicing | 1 | 2011 | 918 | 0.070 |
Why?
|
| BALB 3T3 Cells | 1 | 2006 | 10 | 0.070 |
Why?
|
| Phenotype | 3 | 2010 | 16591 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2010 | 10209 | 0.070 |
Why?
|
| Pan troglodytes | 2 | 2019 | 223 | 0.070 |
Why?
|
| Time Factors | 4 | 2016 | 39967 | 0.070 |
Why?
|
| Mutation | 4 | 2022 | 30052 | 0.070 |
Why?
|
| Surgical Flaps | 1 | 2015 | 1671 | 0.070 |
Why?
|
| Antirheumatic Agents | 1 | 2016 | 1372 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2011 | 1036 | 0.070 |
Why?
|
| Bacillus | 1 | 2006 | 78 | 0.070 |
Why?
|
| Child, Preschool | 7 | 2019 | 42230 | 0.070 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2006 | 151 | 0.070 |
Why?
|
| Anesthesia, General | 1 | 2013 | 1174 | 0.070 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2005 | 14 | 0.070 |
Why?
|
| Nerve Growth Factors | 1 | 2009 | 564 | 0.070 |
Why?
|
| Rodentia | 1 | 2007 | 262 | 0.060 |
Why?
|
| Telemedicine | 2 | 2020 | 3051 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2010 | 1834 | 0.060 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2008 | 459 | 0.060 |
Why?
|
| Integrin alphaV | 1 | 2005 | 54 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 3734 | 0.060 |
Why?
|
| Chromones | 1 | 2005 | 148 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 2319 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 4580 | 0.060 |
Why?
|
| Absorption | 1 | 2005 | 242 | 0.060 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2004 | 353 | 0.060 |
Why?
|
| Fluorometry | 2 | 2016 | 99 | 0.060 |
Why?
|
| Suture Techniques | 2 | 2024 | 769 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2016 | 10445 | 0.060 |
Why?
|
| Pneumonia | 1 | 2016 | 2143 | 0.060 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 2004 | 26 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2021 | 2048 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2005 | 286 | 0.060 |
Why?
|
| Corneal Topography | 2 | 2016 | 68 | 0.060 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2008 | 632 | 0.060 |
Why?
|
| Cell Separation | 1 | 2010 | 1720 | 0.060 |
Why?
|
| Mitomycin | 1 | 2005 | 263 | 0.060 |
Why?
|
| Genetic Loci | 1 | 2013 | 2632 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2020 | 2496 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2008 | 795 | 0.060 |
Why?
|
| Congresses as Topic | 2 | 2020 | 803 | 0.060 |
Why?
|
| Quality of Life | 2 | 2016 | 13367 | 0.060 |
Why?
|
| Interleukin-1beta | 2 | 2020 | 999 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2011 | 1530 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2004 | 1126 | 0.060 |
Why?
|
| Telangiectasis | 1 | 2004 | 78 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2005 | 411 | 0.060 |
Why?
|
| Virus Diseases | 2 | 2017 | 718 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 2155 | 0.050 |
Why?
|
| Ophthalmoscopy | 1 | 2004 | 171 | 0.050 |
Why?
|
| Quinones | 1 | 2003 | 78 | 0.050 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 867 | 0.050 |
Why?
|
| Rifabutin | 1 | 2003 | 59 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2011 | 1974 | 0.050 |
Why?
|
| Anti-Allergic Agents | 1 | 2004 | 153 | 0.050 |
Why?
|
| Ear Cartilage | 1 | 2023 | 62 | 0.050 |
Why?
|
| Periodicals as Topic | 1 | 2014 | 1463 | 0.050 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2003 | 158 | 0.050 |
Why?
|
| beta-Lactam Resistance | 1 | 2023 | 73 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2013 | 1978 | 0.050 |
Why?
|
| Isoindoles | 1 | 2022 | 35 | 0.050 |
Why?
|
| Amphotericin B | 1 | 2023 | 142 | 0.050 |
Why?
|
| Itraconazole | 1 | 2002 | 43 | 0.050 |
Why?
|
| Trifluridine | 1 | 2022 | 28 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 2047 | 0.050 |
Why?
|
| Benzoquinones | 1 | 2003 | 198 | 0.050 |
Why?
|
| Virulence Factors | 1 | 2006 | 513 | 0.050 |
Why?
|
| Androstadienes | 1 | 2004 | 348 | 0.050 |
Why?
|
| Cohort Studies | 8 | 2020 | 41487 | 0.050 |
Why?
|
| Cell Count | 3 | 2012 | 1835 | 0.050 |
Why?
|
| Interleukin-1 | 2 | 2003 | 1248 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2007 | 1246 | 0.050 |
Why?
|
| Morpholines | 1 | 2005 | 581 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 16981 | 0.050 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2002 | 120 | 0.050 |
Why?
|
| Materials Testing | 2 | 2018 | 863 | 0.050 |
Why?
|
| Acrylamides | 1 | 2024 | 260 | 0.050 |
Why?
|
| Macaca | 1 | 2023 | 410 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 3712 | 0.050 |
Why?
|
| Histocytochemistry | 1 | 2003 | 698 | 0.050 |
Why?
|
| Fluconazole | 1 | 2002 | 157 | 0.050 |
Why?
|
| Focal Adhesions | 1 | 2002 | 115 | 0.050 |
Why?
|
| Tissue Donors | 3 | 2018 | 2331 | 0.050 |
Why?
|
| Peyer's Patches | 1 | 2002 | 120 | 0.050 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2002 | 186 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2018 | 2281 | 0.050 |
Why?
|
| Polymyxins | 1 | 2021 | 17 | 0.050 |
Why?
|
| HIV-1 | 1 | 2019 | 6863 | 0.050 |
Why?
|
| Lactams, Macrocyclic | 1 | 2003 | 318 | 0.050 |
Why?
|
| Corynebacterium | 1 | 2021 | 48 | 0.050 |
Why?
|
| Virus Attachment | 1 | 2021 | 55 | 0.050 |
Why?
|
| Up-Regulation | 3 | 2007 | 4124 | 0.050 |
Why?
|
| Ceftazidime | 1 | 2021 | 57 | 0.050 |
Why?
|
| Antibody-Dependent Enhancement | 1 | 2020 | 15 | 0.050 |
Why?
|
| Polymyxin B | 1 | 2020 | 44 | 0.050 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2022 | 163 | 0.050 |
Why?
|
| Benzalkonium Compounds | 1 | 2020 | 21 | 0.050 |
Why?
|
| Amino Acids | 2 | 2022 | 1718 | 0.050 |
Why?
|
| Vitrectomy | 1 | 2024 | 392 | 0.050 |
Why?
|
| Lymphocyte Subsets | 1 | 2002 | 310 | 0.050 |
Why?
|
| Biguanides | 1 | 2020 | 21 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2009 | 2909 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2022 | 435 | 0.050 |
Why?
|
| Health Surveys | 1 | 2010 | 4061 | 0.040 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2016 | 3763 | 0.040 |
Why?
|
| Pinocytosis | 1 | 2020 | 62 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 20098 | 0.040 |
Why?
|
| Ectropion | 1 | 2020 | 27 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 9177 | 0.040 |
Why?
|
| Clathrin-Coated Vesicles | 1 | 2020 | 67 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2023 | 652 | 0.040 |
Why?
|
| Multilocus Sequence Typing | 1 | 2020 | 100 | 0.040 |
Why?
|
| Integrins | 1 | 2004 | 834 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 2645 | 0.040 |
Why?
|
| Pan paniscus | 1 | 2019 | 5 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2005 | 1641 | 0.040 |
Why?
|
| Cell Movement | 2 | 2018 | 5203 | 0.040 |
Why?
|
| Prevalence | 3 | 2021 | 15732 | 0.040 |
Why?
|
| Phenylalanine | 1 | 2021 | 366 | 0.040 |
Why?
|
| Estradiol | 1 | 2007 | 1937 | 0.040 |
Why?
|
| Extracellular Matrix | 2 | 2019 | 1726 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2015 | 7967 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2021 | 595 | 0.040 |
Why?
|
| p21-Activated Kinases | 1 | 2020 | 128 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2015 | 1572 | 0.040 |
Why?
|
| Valine | 1 | 2021 | 408 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2003 | 964 | 0.040 |
Why?
|
| Steroids | 1 | 2004 | 929 | 0.040 |
Why?
|
| Isoelectric Point | 1 | 2019 | 76 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 13380 | 0.040 |
Why?
|
| Decorin | 1 | 2019 | 38 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2012 | 5972 | 0.040 |
Why?
|
| Boston | 1 | 2012 | 9326 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2020 | 283 | 0.040 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2022 | 455 | 0.040 |
Why?
|
| Infant | 5 | 2019 | 36192 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 452 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 1560 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2020 | 748 | 0.040 |
Why?
|
| Conjunctivitis, Viral | 1 | 2018 | 6 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 5789 | 0.040 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 206 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2021 | 437 | 0.040 |
Why?
|
| Burkina Faso | 1 | 2018 | 86 | 0.040 |
Why?
|
| Horses | 1 | 2019 | 300 | 0.040 |
Why?
|
| Sri Lanka | 1 | 2018 | 93 | 0.040 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 2018 | 22 | 0.040 |
Why?
|
| Vancomycin | 1 | 2021 | 503 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2019 | 235 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2005 | 1667 | 0.040 |
Why?
|
| HLA-B Antigens | 1 | 2019 | 317 | 0.040 |
Why?
|
| Sodium Hydroxide | 1 | 2017 | 37 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 778 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2010 | 3242 | 0.040 |
Why?
|
| Proline | 1 | 2019 | 457 | 0.040 |
Why?
|
| Cell Division | 1 | 2004 | 4465 | 0.040 |
Why?
|
| Mice, Inbred DBA | 2 | 2009 | 621 | 0.040 |
Why?
|
| Alleles | 2 | 2019 | 6863 | 0.030 |
Why?
|
| Visual Field Tests | 1 | 2019 | 411 | 0.030 |
Why?
|
| Submandibular Gland | 1 | 2017 | 87 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2021 | 2265 | 0.030 |
Why?
|
| Mitochondria | 1 | 2010 | 3624 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6216 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 2455 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2023 | 22176 | 0.030 |
Why?
|
| Cautery | 1 | 2017 | 71 | 0.030 |
Why?
|
| Uveitis, Anterior | 1 | 2017 | 102 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2019 | 957 | 0.030 |
Why?
|
| Interleukin-18 | 2 | 2009 | 250 | 0.030 |
Why?
|
| Blinking | 1 | 2017 | 133 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2003 | 1486 | 0.030 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2016 | 116 | 0.030 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 2735 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2020 | 675 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2006 | 3208 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2023 | 14666 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2019 | 803 | 0.030 |
Why?
|
| Gels | 1 | 2017 | 420 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 3617 | 0.030 |
Why?
|
| Cytosol | 1 | 2019 | 888 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2018 | 1749 | 0.030 |
Why?
|
| Prosthesis Fitting | 1 | 2015 | 75 | 0.030 |
Why?
|
| Proteome | 2 | 2019 | 1862 | 0.030 |
Why?
|
| Proteins | 1 | 2010 | 6032 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 2016 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 2020 | 1083 | 0.030 |
Why?
|
| Trisomy | 1 | 2016 | 260 | 0.030 |
Why?
|
| Galectins | 1 | 2018 | 295 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2020 | 1204 | 0.030 |
Why?
|
| Artifacts | 1 | 2023 | 1911 | 0.030 |
Why?
|
| Lacrimal Apparatus | 1 | 2017 | 223 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2016 | 527 | 0.030 |
Why?
|
| Organ Preservation | 1 | 2018 | 382 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2020 | 1528 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 2023 | 1334 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 1612 | 0.030 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 321 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2023 | 4278 | 0.030 |
Why?
|
| Collagenases | 1 | 2014 | 222 | 0.030 |
Why?
|
| Brazil | 1 | 2018 | 1230 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2020 | 1264 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2024 | 2979 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2021 | 54425 | 0.030 |
Why?
|
| Trophozoites | 1 | 2013 | 12 | 0.030 |
Why?
|
| International Cooperation | 1 | 2020 | 1422 | 0.030 |
Why?
|
| Sickness Impact Profile | 1 | 2014 | 299 | 0.030 |
Why?
|
| Endotamponade | 1 | 2013 | 37 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2006 | 3847 | 0.030 |
Why?
|
| Immunodiffusion | 1 | 2012 | 141 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 655 | 0.030 |
Why?
|
| Haplorhini | 1 | 2013 | 525 | 0.030 |
Why?
|
| Cholesterol | 2 | 2013 | 2904 | 0.030 |
Why?
|
| Electrochemical Techniques | 1 | 2013 | 94 | 0.030 |
Why?
|
| Aqueous Humor | 1 | 2013 | 153 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2018 | 1186 | 0.030 |
Why?
|
| Infection Control | 1 | 2020 | 981 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2013 | 421 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 1349 | 0.030 |
Why?
|
| Binding Sites | 1 | 2021 | 6055 | 0.030 |
Why?
|
| Air | 1 | 2013 | 187 | 0.030 |
Why?
|
| Intravitreal Injections | 1 | 2014 | 385 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 2012 | 145 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 2012 | 150 | 0.030 |
Why?
|
| Eye Foreign Bodies | 1 | 2013 | 52 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 2112 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2013 | 362 | 0.030 |
Why?
|
| Neoplasms | 1 | 2021 | 22170 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2017 | 1093 | 0.020 |
Why?
|
| Injections | 1 | 1995 | 830 | 0.020 |
Why?
|
| Age Distribution | 1 | 2018 | 2880 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 931 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 1334 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2016 | 1217 | 0.020 |
Why?
|
| Models, Molecular | 2 | 2013 | 5439 | 0.020 |
Why?
|
| Electrophysiological Phenomena | 1 | 2013 | 307 | 0.020 |
Why?
|
| Elastic Modulus | 1 | 2012 | 211 | 0.020 |
Why?
|
| India | 1 | 2018 | 2348 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 2219 | 0.020 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2011 | 143 | 0.020 |
Why?
|
| Indazoles | 1 | 2013 | 304 | 0.020 |
Why?
|
| Shear Strength | 1 | 2011 | 160 | 0.020 |
Why?
|
| Cell Shape | 1 | 2012 | 371 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 2231 | 0.020 |
Why?
|
| Leptin | 1 | 2019 | 1597 | 0.020 |
Why?
|
| Calibration | 1 | 2013 | 818 | 0.020 |
Why?
|
| AIDS Serodiagnosis | 1 | 2012 | 220 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 2016 | 521 | 0.020 |
Why?
|
| Peptides | 1 | 2002 | 4358 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2018 | 1436 | 0.020 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 4243 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2012 | 728 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 2510 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2020 | 4003 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2003 | 4758 | 0.020 |
Why?
|
| Serotyping | 1 | 2010 | 325 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2012 | 755 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2011 | 945 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2016 | 1468 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 2012 | 524 | 0.020 |
Why?
|
| Disease Progression | 2 | 2019 | 13506 | 0.020 |
Why?
|
| Systems Biology | 1 | 2013 | 481 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 3492 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 1435 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 2226 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2013 | 1494 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2010 | 1302 | 0.020 |
Why?
|
| Drainage | 1 | 2014 | 1157 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 491 | 0.020 |
Why?
|
| Prognosis | 3 | 2013 | 29625 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2013 | 1736 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2009 | 1058 | 0.020 |
Why?
|
| Nervous System | 1 | 2011 | 545 | 0.020 |
Why?
|
| Video Recording | 1 | 2013 | 966 | 0.020 |
Why?
|
| Peromyscus | 1 | 2007 | 16 | 0.020 |
Why?
|
| Digoxigenin | 1 | 2007 | 26 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 5671 | 0.020 |
Why?
|
| Sciuridae | 1 | 2007 | 78 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2010 | 5492 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2007 | 129 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2009 | 553 | 0.020 |
Why?
|
| Endoscopy | 1 | 2017 | 1851 | 0.020 |
Why?
|
| Connective Tissue Cells | 1 | 2006 | 49 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2007 | 150 | 0.020 |
Why?
|
| Hospitals | 1 | 2020 | 3882 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2007 | 293 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 2065 | 0.020 |
Why?
|
| Drug Implants | 1 | 2007 | 230 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 3422 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 4063 | 0.020 |
Why?
|
| Immune System | 1 | 2011 | 796 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2006 | 263 | 0.020 |
Why?
|
| Thioredoxins | 1 | 2007 | 202 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2012 | 1509 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 10194 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 1648 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2013 | 3968 | 0.020 |
Why?
|
| Suspensions | 1 | 2004 | 66 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2007 | 731 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2007 | 614 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2007 | 502 | 0.010 |
Why?
|
| Fluorometholone | 1 | 2004 | 4 | 0.010 |
Why?
|
| Fluorescein | 1 | 2004 | 175 | 0.010 |
Why?
|
| Registries | 1 | 2020 | 8224 | 0.010 |
Why?
|
| Consensus | 1 | 2013 | 3123 | 0.010 |
Why?
|
| Cell Death | 1 | 2009 | 1678 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2003 | 364 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2009 | 1722 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15266 | 0.010 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2002 | 47 | 0.010 |
Why?
|
| Trigeminal Ganglion | 1 | 2003 | 190 | 0.010 |
Why?
|
| Reoperation | 1 | 2013 | 4303 | 0.010 |
Why?
|
| Survival Rate | 1 | 2016 | 12725 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2007 | 965 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 4111 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2009 | 2919 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2006 | 1479 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2273 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2018 | 11528 | 0.010 |
Why?
|
| Transfection | 1 | 2009 | 5774 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2004 | 1085 | 0.010 |
Why?
|
| Linear Models | 1 | 2010 | 5871 | 0.010 |
Why?
|
| Safety | 1 | 2004 | 1150 | 0.010 |
Why?
|
| Family | 1 | 2010 | 3194 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2009 | 3442 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 1705 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 4174 | 0.010 |
Why?
|
| Pregnancy | 1 | 2018 | 29874 | 0.010 |
Why?
|
| Immunity | 1 | 2002 | 996 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 17904 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2004 | 8631 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 20570 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 12341 | 0.010 |
Why?
|
| Obesity | 1 | 2010 | 12947 | 0.000 |
Why?
|